Effectiveness and Impact of the 4CMenB Vaccine against Group B Meningococcal Disease in Two Italian Regions Using Different Vaccination Schedules: A Five-Year Retrospective Observational Study (2014–2018)

Background: A few years after the introduction in Italy of a four-component anti-meningococcal B vaccine (4CMenB), we evaluated the effectiveness and impact of vaccination in two regions using different schedules (2, 4, 6, 12 months in Tuscany vs. 7, 9, 15 months in Veneto) through an observational...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Vaccines (Basel)
Главные авторы: Azzari, Chiara, Moriondo, Maria, Nieddu, Francesco, Guarnieri, Valentina, Lodi, Lorenzo, Canessa, Clementina, Indolfi, Giuseppe, Giovannini, Mattia, Napoletano, Giuseppina, Russo, Francesca, Baldovin, Tatjana, Cocchio, Silvia, Ricci, Silvia, Baldo, Vincenzo
Формат: Artigo
Язык:Inglês
Опубликовано: MDPI 2020
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7563708/
https://ncbi.nlm.nih.gov/pubmed/32842669
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/vaccines8030469
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы